593 results on '"Harding, James J."'
Search Results
202. A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC).
203. Imaging of tumor infiltrating T cells with an anti-CD8 minibody (Mb) 89Zr-IAB22M2C, in advanced solid tumors.
204. PRECISE: A clinical-grade automated molecular eligibility screening and just-in-time (JIT) physician decision support solution for molecularly-selected oncology trials.
205. ADI-PEG 20 and FOLFOX6: A phase 1 study in pts (pts) with advanced hepatocellular carcinoma (HCC).
206. In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine
207. Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).
208. Nano-liposomal irinotecan and 5-FU/LV (N+F) for the treatment of advanced PDAC: Memorial Sloan Kettering (MSK) Single Cancer Center Evaluation.
209. Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma
210. PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma
211. OncoKB: A Precision Oncology Knowledge Base
212. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype
213. Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation
214. Reply to: “Adjuvant Medications that Improve Survival after Locoregional Therapy”
215. Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
216. Adjuvant Medications That Improve Survival after Locoregional Therapy
217. Abstract CT090: A phase 1b/2 study of ramucirumab in combination with emibetuzumab in patients with advanced solid tumors
218. A situation where hepatocellular carcinoma (HCC) may be more common in women than men: Clinical and genetic patterns of non risk-factored HCC.
219. Molecular landscape of fibrolamellar carcinoma (FLC): Beyond the DNAJB1-PRKACA chimera.
220. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
221. A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
222. Patient perspectives on ipilimumab across the melanoma treatment trajectory
223. A phase I study of mFOLFOX6 and ADI-PEG-20 in patients (pts) with advanced hepatocellular carcinoma (HCC) and other gastrointestinal (GI) malignancies.
224. Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC).
225. A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC).
226. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference
227. Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma?
228. Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor.
229. Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations.
230. Immunotherapy: A sharp curve turn at the corner of targeted therapy in the treatment of biliary tract cancers
231. Advances in cholangiocarcinoma research:report from the third Cholangiocarcinoma Foundation Annual Conference
232. Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma
233. Acute myeloid leukemia masquerading as hepatocellular carcinoma
234. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC).
235. Comprehensive molecular profiling and analysis of mutual exclusivity of genetic aberrations (MEGA) of intra- and extrahepatic cholangiocarcinomas (IHC and EHC) evaluation of prognostic features and potential targets for intervention.
236. Identification of potentially actionable molecular alterations in advanced hepatocellular carcinoma (HCC).
237. Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.
238. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).
239. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).
240. Genomic profiling of pancreas ductal adenocarcinoma (PDA), actionability, and correlation with clinical phenotype.
241. Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.
242. Emibetuzumab plus ramucirumab: Simultaneous targeting of MET and VEGFR-2 in patients with advanced hepatocellular cancer in a phase 1b/2 study.
243. Horner's Syndrome and Syncope
244. Abstract C49: Phase 1 study of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase in patients with refractory solid tumors
245. A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.
246. A phase IIa/IIb, open-label trial of BI 907828, an MDM2–p53 antagonist, in patients with locally advanced/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: Brightline-2.
247. Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC).
248. Genomic characterization of FGFR -altered solid tumors using a clinically annotated pan-cancer repository.
249. Subacute Abdominal Pain in a Patient With Chronic Liver Disease and Hepatocellular Carcinoma.
250. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.